Breakthroughs in Epilepsy: New Hope for Patients with Lennox-Gastaut Syndrome
Lennox-Gastaut Syndrome is a severe, treatment-resistant form of epilepsy that typically begins between the ages of 3 and 5. It is marked by multiple types of seizures—especially drop seizures that cause sudden falls—as well as significant developmental delays and a characteristic EEG pattern. Though rare, LGS has a devastating impact on quality of life, with most patients requiring lifelong care.
Despite being recognized for decades, LGS has long remained one of the most difficult epilepsy syndromes to manage. Many patients suffer daily seizures despite trying multiple anti-seizure medications. According to recent data, only 11 percent achieve even one year of seizure freedom on drug therapy, and less than 5 percent maintain this long-term.
A Major Development: Fenfluramine Gains Approval in the UK
In a significant milestone earlier this year, the UK's National Institute for Health and Care Excellence (NICE) approved the use of fenfluramine for children and adults aged two and above with Lennox-Gastaut Syndrome. The drug, already in use in the United States for similar indications, demonstrated meaningful reductions in seizure frequency during clinical trials.
NICE's approval includes a provision to reassess patient progress after six months. If seizure frequency is not reduced by at least 30 percent, treatment may be discontinued. Experts say this ensures both clinical effectiveness and responsible healthcare spending.
Families and advocacy groups have welcomed the move, calling it a "game-changer" for those previously left with limited treatment options.
Innovation in the Pipeline
The approval of fenfluramine is only one part of the story. Several other promising therapies are currently in development or clinical trials.
Soticlestat, a novel compound developed by Takeda Pharmaceuticals, showed mixed results in late-stage trials. While it did not meet its primary endpoint in seizure frequency reduction, some improvements were seen in secondary outcomes such as seizure intensity and quality of life.
Two other medications—bexicaserin and BMB-101—are also in the pipeline. Both are designed to selectively activate serotonin 5-HT2C receptors, targeting seizure pathways without some of the cardiac risks associated with older serotonergic drugs.
Meanwhile, researchers continue to explore surgical and neurostimulation approaches. Vagus nerve stimulation (VNS) remains a standard option, but deep brain stimulation (DBS) is gaining traction.
World-First Implant Offers New Possibilities
In June 2024, a 13-year-old boy in the UK with LGS became the first patient globally to receive a brain implant designed to prevent seizures. The procedure involved implanting a deep brain stimulation device into his thalamus—a critical relay center in the brain.
The outcome has been described as remarkable. The patient experienced an 80 percent reduction in daytime seizures and showed improved social engagement and alertness. Doctors involved in the trial believe this could revolutionize treatment for drug-resistant epilepsies like LGS, especially in pediatric cases.
This pioneering work is part of a larger trial expected to expand in the coming year, focusing on patients with the most treatment-resistant forms of epilepsy.
Other Advances and Market Trends
The ketogenic diet continues to serve as a valuable adjunct treatment, particularly for children. It is often prescribed alongside anti-seizure drugs to help control seizure activity through metabolic changes.
Researchers funded by the LGS Foundation are also investigating the use of focused ultrasound, a non-invasive technique that could one day replace certain types of epilepsy surgery. In another ongoing study, wearable sleep-tracking devices are being used to monitor and predict seizures, with the goal of developing responsive therapies that adjust to a patient’s real-time neurological state.
As innovation accelerates, the global market for LGS treatments is expected to grow. The anti-seizure medication market alone is projected to rise from $1.3 billion in 2024 to nearly $1.9 billion by 2029. The broader therapies market, which includes devices, diagnostics, and emerging gene-based treatments, may approach $1 billion in the same timeframe.
Persistent Challenges Remain
Despite the flurry of innovation, managing LGS remains a significant challenge. Many treatments offer only partial relief, and side effects can be considerable. For example, while fenfluramine has shown efficacy, its use is carefully monitored due to potential cardiac side effects. Felbamate, another potent anti-seizure drug, has limited use due to the risk of liver toxicity.
Furthermore, access to advanced treatments varies widely by region, with families in low-resource settings often facing significant barriers.
Advocates stress the need for a multidisciplinary approach to care—one that addresses not just seizures but also developmental, behavioral, and emotional aspects of the disorder. This includes collaboration among neurologists, developmental pediatricians, speech and occupational therapists, and caregivers.